🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is Page 5

Can we talk about how SLOW the FDA is

KarenAZ_mom Mon, Apr 20, 2026 at 10:27 AM 38 replies 1,036 viewsPage 5 of 8
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Apr 26, 2026 at 12:24 PM#21

Clinical perspective, offered as context rather than as advice. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

Last edited: Apr 26, 2026 at 3:24 PM
5 5labquiet_amy, emily_PDX, Dr.SleepRoch and 2 others
Reply Quote Save Share Report
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Apr 28, 2026 at 2:43 PM#22
carl_compliance said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Second this.

4 4lucas_SP_BR, lisa_labSD, adam_van and 1 other
Reply Quote Save Share Report
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Apr 30, 2026 at 5:01 PM#23
carl_compliance said:
Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the…

Coming at carl_compliance’s question from a different direction. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

3 3adam_van, Dr.SurgeonPGH, rachel_ABQ
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
May 2, 2026 at 7:18 PM#24

The figures, for anyone assembling their own picture. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

2 2Dr.CardioMD, EndoResFellow
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
May 4, 2026 at 9:34 PM#25

One thing that is still open after carl_compliance’s answer:

How would you tell the difference between that and the alternative explanation?

1 1pat_auckland
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register